Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in LondonNoticia de empresa11 nov 2026ENPharming Group N.V.Company newsroom
MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.Noticia de empresa6 nov 2026ENPharming Group N.V.Company newsroom
Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in NovemberNoticia de empresa27 oct 2026ENPharming Group N.V.Company newsroom
Pharming Group announces third quarter 2026 revenues above market expectationsNoticia de empresa22 oct 2026ENPharming Group N.V.Company newsroom
Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026Noticia de empresa14 oct 2026ENPharming Group N.V.Company newsroom
Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDSNoticia de empresa25 sept 2026ENPharming Group N.V.Company newsroom
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026Noticia de empresa22 sept 2026ENPharming Group N.V.Company newsroom
FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.Noticia de empresa11 sept 2026ENPharming Group N.V.Company newsroom
Pharming Group to participate in September investor conferencesNoticia de empresa9 sept 2026ENPharming Group N.V.Company newsroom
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and olderNoticia de empresa13 ago 2026ENPharming Group N.V.Company newsroom
Pharming Group to participate in Canaccord Genuity 46th Annual Growth ConferenceNoticia de empresa4 ago 2026ENPharming Group N.V.Company newsroom
Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic useNoticia de empresa30 jul 2026ENPharming Group N.V.Company newsroom
Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30Noticia de empresa16 jul 2026ENPharming Group N.V.Company newsroom
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDSNoticia de empresa4 jun 2026ENPharming Group N.V.Company newsroom
Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New YorkNoticia de empresa2 jun 2026ENPharming Group N.V.Company newsroom
Pharming Group announces results of 2026 Annual General Meeting of ShareholdersNoticia de empresa28 may 2026ENPharming Group N.V.Company newsroom
European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European UnionNoticia de empresa22 may 2026ENPharming Group N.V.Company newsroom
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026Noticia de empresa7 may 2026ENPharming Group N.V.Company newsroom
Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disordersNoticia de empresa7 may 2026ENPharming Group N.V.Company newsroom